Genocea Biosciences Inc. buy fchar99
Summary
This prediction ended on 10.12.18 with a price of €4.42. The price of Genocea Biosciences Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -23.36%. fchar99 has 50% into this predictionGenocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Genocea Biosciences Inc. | - | - | - | - |
iShares Core DAX® | -0.372% | 5.236% | 16.908% | 16.016% |
iShares Nasdaq 100 | -1.950% | 1.680% | 19.890% | 31.832% |
iShares Nikkei 225® | -1.690% | 7.286% | 12.202% | 3.400% |
iShares S&P 500 | -0.399% | 2.379% | 20.975% | 36.224% |
Comments by fchar99 for this prediction
In the thread Genocea Biosciences Inc. diskutieren
fchar99 agrees with Mori8's Buy-prediction
On 10/09/2018, fchar99 agrees with Mori8's' Buy-prediction with a target price of €0.88.
Title: Mori8 stimmt der Buy-Einschätzung von Quitte zu